Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Rating of "Moderate Buy" from Analysts
Esperion Therapeutics, Inc. (NASDAQ:ESPR) has received a "Moderate Buy" consensus rating from eight analysts, with an average one-year price target of $7.60. Despite missing EPS estimates slightly, the company exceeded revenue expectations. Institutional investors, including Vanguard and State Street, have increased their stakes, with institutions now owning approximately 47.39% of the company.
Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co.
JPMorgan Chase & Co. has significantly increased its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 68.4% in the third quarter of 2025, now owning 945,491 shares valued at approximately $2.51 million. This increase follows Esperion's acquisition of Corstasis and a $50 million Japan royalty financing deal, both aimed at boosting portfolio diversification and liquidity. While analysts have mixed views with some lowering near-term EPS estimates, the consensus still reflects a "Moderate Buy" rating with a target price of $7.60, anticipating profitability by 2027-2028.
ESPR Financials: Revenue Breakdown, Margins & Competitor Comparison
This article analyzes Esperion Therapeutics Inc.'s (ESPR) financial performance, focusing on its profitability and margins. ESPR boasts a gross margin of 83.46%, an operating margin of 50.60%, and a net margin of 36.71%. The company is benchmarked against competitors MNKD and OMER, highlighting its strong gross margin compared to MNKD.
Esperion (ESPR) highlights inclusion of bempedoic acid in 2026 ACC/AHA dyslipidemia guidelines
Esperion (ESPR) announced the inclusion of bempedoic acid in the 2026 American College of Cardiology (ACC) and American Heart Association (AHA) dyslipidemia guidelines. This recognition is significant for the company as it validates the clinical utility of their lead product in managing lipid disorders. The updated guidelines are expected to reinforce the importance of bempedoic acid in treatment protocols, potentially boosting its adoption and market presence.
Esperion Completes Corstasis Acquisition, Expands Cardiovascular Portfolio
Esperion Therapeutics has completed its acquisition of Corstasis Therapeutics, expanding its cardiovascular portfolio with the addition of the FDA-approved nasal spray Enbumyst. This move was supported by a $25 million term loan and the sale of up to $100 million in future royalty and milestone receivables. Despite the strategic expansion, an AI analyst from TipRanks maintains a neutral outlook on Esperion stock due to weak financial structure, negative equity, and ongoing net losses.
Esperion Therapeutics Closes Acquisition of Corstasis
Esperion Therapeutics has completed its acquisition of Corstasis Therapeutics, integrating Enbumyst™ (bumetanide nasal spray) into its cardiovascular franchise. This acquisition expands Esperion's portfolio with the first and only FDA-approved nasal spray loop diuretic, aiming to improve fluid management for congestive heart failure patients and drive revenue growth. Esperion plans to leverage its existing commercial infrastructure to maximize patient access and accelerate the adoption of Enbumyst.
Esperion Therapeutics Inc. (ESPR) has entered into a new financial arrangement with the Athyrium Fund.
Esperion Therapeutics Inc. (ESPR) has secured a new financial arrangement with the Athyrium Fund. This agreement grants Athyrium tiered royalties on Esperion's net sales, ranging from 12% to 33%, along with milestone payments. These financial benefits will continue until Athyrium achieves a total return of 2.0 times its initial investment.
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
Athyrium Capital Management and Esperion Therapeutics have finalized a $50 million royalty financing agreement. This deal involves Athyrium Funds acquiring Esperion's royalty interest in Otsuka's bempedoic acid products sold in Japan, along with related milestone payments, providing Esperion with non-dilutive capital. The financing will primarily support Esperion's recent acquisition of Corstasis Therapeutics Inc., a company specializing in cardiovascular treatments, and specifically its FDA-approved drug Enbumyst™.
Esperion (ESPR) acquires Corstasis, adds $25M term loan and $50M royalty sale
Esperion Therapeutics has acquired Corstasis Therapeutics for $75 million upfront, plus potential milestones, gaining the FDA-approved nasal spray loop diuretic, Enbumyst. To finance the deal, Esperion secured an additional $25 million term loan and sold $50 million of Bempedoic Acid royalties to Athyrium, which will receive 100% of these royalties until $100 million is collected. This strategic move aims to expand Esperion's cardiometabolic portfolio and leverage its existing commercial infrastructure.
Esperion Adds $25 Million Term Loans, Sells $50 Million Otsuka Royalties to Fund Corstasis Buy
Esperion Therapeutics has secured additional financing by adding $25 million in term loans and monetizing $50 million of royalties from its Otsuka-partnered products. These agreements aim to support the acquisition of Corstasis and enhance the company's liquidity. The royalty monetization involves the purchaser receiving 100% of receivables until $100 million is collected, after which they fully revert to Esperion.
Esperion Therapeutics Inc. (ESPR) has entered into a new financial arrangement with the Athyrium Fund.
Esperion Therapeutics Inc. (ESPR) has secured a new financial arrangement with the Athyrium Fund. Under this agreement, Athyrium Fund will receive tiered royalties from Esperion's net sales, ranging from 12% to 33%, along with milestone payments. These benefits will continue until Athyrium Fund achieves a total return of 2.0 times its initial investment.
Esperion Therapeutics Inc. has successfully secured financing, which will be specifically used to support its acquisition of Corstasis Therapeutics.
Esperion Therapeutics Inc. has secured financing to acquire Corstasis Therapeutics, the developer of the innovative drug Enbumyst. This acquisition is expected to significantly enhance Esperion's R&D pipeline and market competitiveness in the relevant therapeutic field. The information is not intended as investment advice.
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeutics
Athyrium Capital Management and Esperion Therapeutics have announced a $50 million royalty financing agreement. Athyrium Funds will acquire Esperion's royalty interest in Otsuka's bempedoic acid products in Japan, along with related milestone payments, subject to a cap. This non-dilutive capital will support Esperion's acquisition of Corstasis Therapeutics Inc., which developed Enbumyst™, the first FDA-approved intranasal loop diuretic.
Esperion Therapeutics Closes Acquisition of Corstasis
Esperion Therapeutics has completed its acquisition of Corstasis Therapeutics, bringing Enbumyst, an FDA-approved nasal spray loop diuretic, into its cardiovascular portfolio. This strategic move aims to expand Esperion's offerings for managing edema associated with cardiovascular, hepatic, and renal diseases, leveraging existing commercial infrastructure to drive growth. The acquisition aligns with Esperion's Vision 2040, strengthening its presence in cardiometabolic risk management.
Esperion Therapeutics Inc. has successfully secured financing, which will be specifically used to support its acquisition of Corstasis Therapeutics.
Esperion Therapeutics Inc. has successfully secured financing to support its acquisition of Corstasis Therapeutics. This strategic move aims to enhance Esperion's R&D pipeline and market competitiveness by integrating Corstasis Therapeutics, the developer of the innovative drug Enbumyst. The article, originally from老虎证券, highlights the significance of this acquisition for Esperion's future growth.
Zacks Research Has Negative Forecast for ESPR Q2 Earnings
Zacks Research has issued a negative forecast for Esperion Therapeutics' (ESPR) Q2 2026 earnings, cutting its EPS estimate and predicting a full-year loss for 2026 before a return to profitability in 2027. Despite the negative earnings outlook, the biopharmaceutical company holds a "Moderate Buy" consensus rating from analysts with an average price target of $7.60, as many firms have raised their ratings or price objectives. Esperion's shares opened down about 4.7% following the news, with the company recently missing its prior quarterly EPS estimate but exceeding revenue expectations.
Esperion Therapeutics Nears a Crucial Profitability Milestone
Despite recent selling pressure, Esperion Therapeutics is showing signs of a turnaround, with market experts revising earnings forecasts upwards and predicting sustained profitability by 2027. The company is set to present its commercial progress at the Needham Virtual Healthcare Conference on April 13, 2026, where it will detail advancements for its cholesterol-lowering therapies. This event is crucial for validating increasingly optimistic earnings estimates and demonstrating the company's shift toward commercial viability.
Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing
Athyrium Capital Management and Esperion Therapeutics have announced a $50 million royalty financing agreement. This deal grants Athyrium funds 100% of Esperion's royalty interest from Otsuka Pharmaceutical Co., Ltd.'s net sales of bempedoic acid products in Japan, along with related milestone payments, until aggregate payments reach 2.0x their investment. The financing provides Esperion with non-dilutive capital to support its recent acquisition of Corstasis Therapeutics, Inc.
New Analyst Updates: $9 and $16 Price Targets on Esperion Therapeutics Signal Major Upside From $2.63
Esperion Therapeutics (ESPR) is highlighted as a deeply mispriced small-cap biotech with significant upside potential, according to recent analyst commentary from Piper Sandler and H.C. Wainwright, which set price targets of $9 and $16 respectively. The bullish thesis is supported by new cardiovascular guidelines expanding the market for its core asset, benpedoic acid, strong CLEAR Outcomes data validating its efficacy, accelerating commercial momentum, and potential European expansion. The company is also seen as a strong strategic takeover target due to its de-risked commercial stage, growing revenue, and improving balance sheet trajectory.
Q4 EPS Estimate for Esperion Therapeutics Raised by Analyst
Zacks Research has increased its Q4 2026 EPS estimate for Esperion Therapeutics (ESPR) to $0.04, up from $0.03, and provided positive forward estimates for 2027 and 2028. The biopharmaceutical company, which has seen mixed but improving analyst coverage and several price target increases, recently reported Q4 EPS of $0.22, missing estimates slightly but exceeding revenue expectations. Esperion Therapeutics is focused on developing therapies for atherosclerotic cardiovascular disease, with its shares currently trading around $2.74 and a market capitalization of approximately $702 million.
Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference
Esperion (NASDAQ: ESPR) announced its participation in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET. The company is a commercial-stage biopharmaceutical firm focused on cardiometabolic and rare/orphan disease therapies, leveraging its expertise in ACLY biology. Esperion currently markets two oral non-statin therapies for LDL-C management and is expanding its pipeline with novel product candidates.
H.C. Wainwright Maintains Esperion Therapeutics(ESPR.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright has reiterated its Buy rating on Esperion Therapeutics (ESPR.US) and maintained its target price at $16. This indicates continued confidence from the analyst firm in the company's stock performance and future prospects.
Investors can watch Esperion at Needham's virtual healthcare event
Esperion (NASDAQ: ESPR) is scheduled to participate in the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET. The company, a commercial-stage cardiometabolic biopharmaceutical firm, will provide a live webcast of its presentation on its investor site, with a replay available for approximately 90 days afterward. Investors can expect details on the company's marketed LDL-C therapies and its R&D pipeline for ACLY biology, Primary Sclerosing Cholangitis, and renal diseases.
Esperion Showcases New Data from CLEAR Outcomes
Esperion announced new post-hoc analyses from its CLEAR Outcomes trial, highlighting the effectiveness of bempedoic acid (NEXLETOL). The data revealed a 22% reduced risk of ischemic stroke for patients taking bempedoic acid and showed that it reduced major adverse cardiovascular events in high-risk patients with autoimmune or inflammatory diseases similarly to those without such conditions. These findings underscore the drug's value in reducing cardiovascular risk across diverse patient populations, particularly for statin-intolerant individuals.
Esperion Therapeutics unveils new CLEAR Outcomes data on NEXLETOL at ACC Annual Scientific Session
Esperion Therapeutics presented new data from its CLEAR Outcomes study on its cholesterol-lowering therapy NEXLETOL at the American College of Cardiology’s Annual Scientific Session 2026. The company aims to highlight the therapeutic impact of NEXLETOL for cardiovascular patients, with the new data potentially influencing future treatment guidelines. This presentation reflects Esperion's ongoing focus on cardiovascular therapies and clinical research, following their previous announcement to acquire Corstasis Therapeutics.
Vanguard (ESPR) Amendment: Reports zero ESPR common shares after internal realignment
Vanguard Group has filed an amendment (Schedule 13G/A) reporting zero beneficial ownership of Esperion Therapeutics Inc. (ESPR) common stock. This change reflects an internal realignment effective January 12, 2026, which causes certain Vanguard subsidiaries to report their beneficial ownership separately. The filing clarifies that Vanguard itself no longer holds nor is deemed to hold beneficial ownership over the securities managed by these disaggregated subsidiaries.
Esperion Therapeutics prices $75M public offering
This article states that Esperion Therapeutics has priced a $75 million public offering. The content available is extremely limited, only stating this single piece of information.
Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines
Esperion (ESPR) announced the inclusion of its drug, bempedoic acid, in the 2026 American College of Cardiology/American Heart Association Multisociety Guideline for managing dyslipidemia. This guideline supports the use of bempedoic acid to lower LDL-C and reduce cardiovascular risk, especially for patients unable to tolerate statins. Citizens also raised Esperion's price target to $5 from $4, maintaining an Outperform rating, following consistent Q4 results and progress in its Vision 2040 strategy.
Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference
Esperion Therapeutics reported a strong 2025 with 38% revenue growth and 34% total prescription growth, with momentum continuing into 2026. The company is acquiring Corstasis and its nasal heart-failure drug ENBUMYST, aiming to integrate it into Esperion's commercial footprint and leverage its existing prescriber base. Esperion also plans to become cash-generating in 2026, further deleverage, and continues to highlight the bempedoic acid franchise as a significant market opportunity with strong international partner performance.
Esperion Therapeutics CFO Halladay sells $17k in stock
Esperion Therapeutics CFO Benjamin Halladay sold 6,424 shares of company stock for $17,376 to cover tax obligations. Despite recent weakness, the stock has shown a strong 72% return over the past year, and analysts anticipate profitability for the company this year. Recent company news includes strong revenue growth in Q4 2025, positive guideline recommendations for its drugs, and mixed analyst ratings.
Esperion (ESPR) CFO sells shares to cover taxes on vested RSUs
Esperion Therapeutics CFO Benjamin Halladay sold 6,424 shares of the company's common stock at $2.705 per share to cover tax obligations on vested restricted stock units. This transaction, reported in an SEC Form 4 filing, leaves him with 713,602 direct shares. The sale is categorized as tax-related and not a discretionary reduction of his equity stake in Esperion.
Esperion Therapeutics (NASDAQ:ESPR) CFO Sells $17,409.04 in Stock
Esperion Therapeutics (NASDAQ:ESPR) CFO Benjamin Halladay sold 6,424 shares valued at $17,409.04, reducing his stake by 0.89%. The company recently reported Q4 EPS of $0.22, missing estimates, but revenue of $168.45M exceeded expectations. Analysts currently have a "Moderate Buy" consensus rating for ESPR with an average price target of $7.60.
Insider Selling: Esperion Therapeutics (NASDAQ:ESPR) Insider Sells $15,411.60 in Stock
Esperion Therapeutics (NASDAQ:ESPR) insider Benjamin Looker sold 5,708 shares of the company's stock for $15,411.60 on March 17th, reducing his position by 0.83%. Despite recent earnings missing estimates by a small margin, Esperion has a consensus "Moderate Buy" rating from analysts with an average price target of $7.60. The company's stock currently trades at $2.51, below its 50-day simple moving average.
Esperion (NASDAQ: ESPR) CLO sells 5,708 shares to cover RSU tax bill
Esperion Therapeutics' Chief Legal Officer, Benjamin Looker, sold 5,708 shares of common stock at $2.703 per share to cover tax obligations on vested restricted stock units. This administrative transaction is a common practice for handling equity-compensation taxes and represents a small fraction of his overall holdings, as he still directly owns 679,348 shares. The sale is considered to have limited signaling value regarding management's view of the stock.
Esperion Therapeutics (ESPR) CEO sells shares to pay RSU taxes
Esperion Therapeutics' President and CEO, Sheldon L. Koenig, sold 25,578 shares of common stock at $2.719 per share. This transaction was carried out to fulfill tax obligations linked to vested restricted stock units. After the sale, Koenig still holds a significant stake of 2,172,699 shares in the company, indicating it was a tax-related disposition rather than a discretionary reduction in his holdings.
Esperion Therapeutics CFO Halladay sells $17k in stock
Esperion Therapeutics CFO Benjamin Halladay sold 6,424 shares of company stock worth $17,376 to cover tax obligations. Following the sale, Halladay directly owns 713,602 shares. The company recently reported Q4 2025 earnings with strong revenue growth and received positive recommendations for its bempedoic acid, though analyst opinions on its future performance are mixed.
Esperion Therapeutics (NASDAQ:ESPR) Stock Price Down 7.6% - Here's What Happened
Esperion Therapeutics (NASDAQ:ESPR) saw its stock price drop 7.6% on Wednesday to $2.505, with trading volume significantly lower than average. Despite the decline, analysts maintain a "Moderate Buy" consensus rating and an average price target of $7.60, following recent upgrades. The biopharmaceutical company recently reported Q4 EPS of $0.22, missing estimates by $0.01, but revenue slightly beat expectations at $168.45 million.
Q1 EPS Estimate for Esperion Therapeutics Lowered by Analyst
HC Wainwright has lowered its Q1 2026 EPS estimate for Esperion Therapeutics (NASDAQ:ESPR) to ($0.09) from ($0.08), while maintaining a "Buy" rating. Despite the lowered estimate, the consensus analyst rating remains a "Moderate Buy" with an average target price of $7.60. Esperion Therapeutics' shares opened at $2.71, and the company recently reported Q4 EPS of $0.22, missing estimates by $0.01 but exceeding revenue expectations.
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
Esperion announced that two abstracts from its CLEAR Outcomes trial have been accepted for presentation at the American College of Cardiology's 2026 Annual Scientific Session. These analyses will discuss bempedoic acid's role in reducing cardiovascular risk in statin-intolerant patients and those with autoimmune or inflammatory diseases. The presentations aim to share new insights into diverse patient populations.
Esperion shares rise 8% after revenue tops forecasts and acquisition announced
NULL
ESPR (NASDAQ: ESPR) Form 144 files planned sale of 5,708 shares
A Form 144 filing indicates a planned sale of 5,708 shares of Esperion Therapeutics, Inc. (ESPR) common stock by Benjamin Looker, tied to restricted stock vesting on March 16, 2026. The filing also discloses previous dispositions of 6,517 shares on December 17, 2025, and 1,689 shares on January 20, 2026. Fidelity Brokerage Services LLC is named as the broker/agent for the upcoming sale.
Sheldon Koenig to sell 25,578 ESPR shares (NASDAQ: ESPR) under Form 144
Sheldon Koenig has filed a Form 144 indicating an intent to sell 25,578 shares of Esperion Therapeutics (NASDAQ: ESPR) common stock. These shares resulted from restricted stock vesting on March 16, 2026. The filing also disclosed a prior sale of 48,244 shares on December 17, 2025, for $177,200.21, and names Fidelity Brokerage Services LLC as the broker for the proposed transaction.
ESPR (NASDAQ: ESPR) affiliate files to sell 6,424 vested shares after vesting
Esperion Therapeutics (NASDAQ: ESPR) filed a Form 144, indicating a proposed sale of 6,424 common shares linked to restricted stock vesting on March 16, 2026. The filing also disclosed a prior sale of 7,337 shares on December 17, 2025, for $26,906.25. This regulatory notice signals an affiliate's intent to sell resalable securities under Rule 144, with the shares to be sold via Fidelity Brokerage Services LLC.
Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session
Esperion announced that two abstracts from its CLEAR Outcomes clinical trial have been accepted for presentation at the American College of Cardiology’s 2026 Annual Scientific Session. The presentations will cover new analyses regarding bempedoic acid's effect on stroke incidence in statin-intolerant patients and cardiovascular outcomes in patients with autoimmune or inflammatory diseases. These analyses aim to provide deeper insights into cardiovascular risk reduction for diverse patient populations needing alternatives to statins.
Esperion to Present Two New Analyses from CLEAR Outcomes
Esperion announced that two abstracts from its CLEAR Outcomes trial will be presented at the American College of Cardiology's 2026 Annual Scientific Session. These analyses will provide new insights into cardiovascular risk reduction for diverse patient populations, specifically focusing on statin-intolerant patients and those with autoimmune or inflammatory diseases. The presentations aim to reinforce bempedoic acid's role as a therapeutic option for patients needing alternatives to statins.
Esperion Therapeutics (ESPR) CFO receives major equity grants
Esperion Therapeutics CFO Benjamin Halladay received significant equity awards, including 221,270 stock options with an exercise price of $2.44 and 247,430 shares of common stock. These grants increase his direct holdings to 720,026 shares, which also include 5,071 shares from the company's Employee Stock Purchase Plan. The stock options will vest over four years in equal quarterly installments, beginning June 15, 2026.
[Form 4] Esperion Therapeutics, Inc. Insider Trading Activity
Esperion Therapeutics, Inc. President and CEO Sheldon L. Koenig received new equity awards, including a stock option for 647,460 shares and a grant of 723,760 shares of common stock, both vesting over four years. These awards were issued at no cash cost to Koenig, with the stock option having an exercise price of $2.44 per share. Following these transactions, Koenig directly holds 2,198,277 shares of Esperion common stock.
Esperion (ESPR) CLO receives new stock and option grants
Esperion Therapeutics Chief Legal Officer Benjamin Looker was granted 269,230 stock options with an exercise price of $2.44 per share, expiring in 2036, and 300,840 shares of common stock. These equity awards increase his total direct common stock holdings to 685,056 shares. The stock option award will vest over four years in equal quarterly installments, beginning June 15, 2026.
Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia
Esperion's bempedoic acid has received multiple Class 1 recommendations in the 2026 ACC/AHA Multisociety Guideline for the Management of Dyslipidemia, validating its role in lowering LDL-C and reducing cardiovascular risk. The guidelines emphasize earlier, aggressive combination therapy and acknowledge statin intolerance, providing evidence-based recommendations for escalating treatment beyond statins. This recognition is expected to accelerate the adoption and access of NEXLETOL and NEXLIZET for patients unable to tolerate statins or requiring additional LDL-C lowering.
2026 cholesterol guideline backs bempedoic acid for statin-intolerant patients
Esperion (NASDAQ: ESPR) announced that its bempedoic acid received multiple Class 1 recommendations in the 2026 ACC/AHA multisociety dyslipidemia guideline, including for statin-intolerant patients and those with severe hypercholesterolemia. The guideline positions bempedoic acid alongside ezetimibe and PCSK9 mAb after statins and reintroduces LDL-C targets, reinforcing its role in reducing ASCVD risk. Following this news, Esperion's stock saw a positive market reaction, increasing by 5.94%.
